Vutrisiran Snags FDA Approval for TTR Amyloidosis Cardiomyopathy

[ad_1]

(MedPage Today) — Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals announced expanded FDA approval.
Vutrisiran, a transthyretin-directed…

[ad_2]

Source link : https://www.medpagetoday.com/cardiology/chf/114771

Author :

Publish date : 2025-03-21 17:09:00

Copyright for syndicated content belongs to the linked Source.